Skip to content

Study · Animal study (in vivo) · mouse · 2017

9 results

Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis.

Xiao B, Xu Z, Viennois E, Zhang Y, Zhang Z, Zhang M, Han MK, Kang Y, Merlin D

Molecular therapy : the journal of the American Society of Gene Therapy28 Jan 2017Cited by 135 (Europe PMC)

PMID28143741 (opens in a new tab)PMCIDPMC5498804 (opens in a new tab)DOI10.1016/j.ymthe.2016.11.020 (opens in a new tab)PepBankPUB-28143741
Read at sourcePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study9

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In a mouse model of ulcerative colitis, HA-KPV-NPs accelerated mucosal healing.

    In plain wordsIn mice with colitis, nanoparticles carrying KPV sped up healing of the gut lining.

    Peptide
    KPV
    Outcome
    IncreaseAccelerated mucosal healing
    Study

    mousen: not reported in source

    ulcerative colitis
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Intriguingly, we found that HA-KPV-NPs exert combined effects against UC by both accelerating mucosal healing and alleviating inflammation.
    2 context sentences
    Summary · context
    Oral administration of HA-KPV-NPs encapsulated in a hydrogel (chitosan/alginate) exhibited a much stronger capacity to prevent mucosa damage and downregulate TNF-α, thus they showed a much better therapeutic efficacy against UC in a mouse model, compared with a KPV-NP/hydrogel system.
    Summary · context
    Here, we loaded KPV into hyaluronic acid (HA)-functionalized polymeric nanoparticles (NPs).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In a mouse model of ulcerative colitis, HA-KPV-NPs alleviated inflammation.

    In plain wordsIn mice with colitis, nanoparticles carrying KPV reduced gut inflammation.

    Peptide
    KPV
    Outcome
    DecreaseAlleviation of inflammation
    Study

    mousen: not reported in source

    ulcerative colitis
    Outcome group
    Inflammation markers · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Intriguingly, we found that HA-KPV-NPs exert combined effects against UC by both accelerating mucosal healing and alleviating inflammation.
    2 context sentences
    Summary · context
    Oral administration of HA-KPV-NPs encapsulated in a hydrogel (chitosan/alginate) exhibited a much stronger capacity to prevent mucosa damage and downregulate TNF-α, thus they showed a much better therapeutic efficacy against UC in a mouse model, compared with a KPV-NP/hydrogel system.
    Summary · context
    Here, we loaded KPV into hyaluronic acid (HA)-functionalized polymeric nanoparticles (NPs).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice with ulcerative colitis, oral HA-KPV-NPs in a hydrogel prevented mucosa damage more strongly than the KPV-NP/hydrogel system.

    In plain wordsIn mice with colitis, KPV nanoparticles with hyaluronic acid prevented gut damage better than KPV nanoparticles without it.

    Peptide
    KPV
    Outcome
    DecreasePrevention of mucosa damage
    Study

    mousen: not reported in source

    ulcerative colitis
    Comparator
    KPV-NP/hydrogel system
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated · oralAs given in this study (mouse).

    Source sentences

    Summary
    Oral administration of HA-KPV-NPs encapsulated in a hydrogel (chitosan/alginate) exhibited a much stronger capacity to prevent mucosa damage and downregulate TNF-α, thus they showed a much better therapeutic efficacy against UC in a mouse model, compared with a KPV-NP/hydrogel system.
    1 context sentence
    Summary · context
    Here, we loaded KPV into hyaluronic acid (HA)-functionalized polymeric nanoparticles (NPs).
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice with ulcerative colitis, oral HA-KPV-NPs in a hydrogel downregulated TNF-α more strongly than the KPV-NP/hydrogel system.

    In plain wordsIn mice with colitis, KPV nanoparticles with hyaluronic acid lowered TNF-α more than KPV nanoparticles without it.

    Peptide
    KPV
    Outcome
    DecreaseTNF-α downregulation
    Study

    mousen: not reported in source

    ulcerative colitis
    Comparator
    KPV-NP/hydrogel system
    Outcome group
    Inflammation markers · Gastrointestinal
    Studied dose
    Dose not stated · oralAs given in this study (mouse).

    Source sentences

    Summary
    Oral administration of HA-KPV-NPs encapsulated in a hydrogel (chitosan/alginate) exhibited a much stronger capacity to prevent mucosa damage and downregulate TNF-α, thus they showed a much better therapeutic efficacy against UC in a mouse model, compared with a KPV-NP/hydrogel system.
    1 context sentence
    Summary · context
    Here, we loaded KPV into hyaluronic acid (HA)-functionalized polymeric nanoparticles (NPs).
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In a mouse model of ulcerative colitis, oral HA-KPV-NP/hydrogel showed much better therapeutic efficacy than the KPV-NP/hydrogel system.

    In plain wordsIn mice with colitis, KPV nanoparticles with hyaluronic acid worked better than KPV nanoparticles without it.

    Peptide
    KPV
    Outcome
    IncreaseTherapeutic efficacy against UC
    Study

    mousen: not reported in source

    ulcerative colitis
    Comparator
    KPV-NP/hydrogel system
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated · oralAs given in this study (mouse).

    Source sentences

    Summary
    Oral administration of HA-KPV-NPs encapsulated in a hydrogel (chitosan/alginate) exhibited a much stronger capacity to prevent mucosa damage and downregulate TNF-α, thus they showed a much better therapeutic efficacy against UC in a mouse model, compared with a KPV-NP/hydrogel system.
    1 context sentence
    Summary · context
    Here, we loaded KPV into hyaluronic acid (HA)-functionalized polymeric nanoparticles (NPs).
  6. 06LabIn vitro (cells)Other

    The nanoparticles successfully delivered KPV to colonic epithelial cells and macrophages, the key cells for ulcerative colitis therapy.

    In plain wordsIn cells, the nanoparticles delivered KPV to the colon cell types that matter in ulcerative colitis.

    Peptide
    KPV
    Outcome
    Not applicableTargeted delivery of KPV to colonic epithelial cells and macrophages
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    These NPs successfully mediated the targeted delivery of KPV to key UC therapy-related cells (colonic epithelial cells and macrophages).
    1 context sentence
    Summary · context
    Here, we loaded KPV into hyaluronic acid (HA)-functionalized polymeric nanoparticles (NPs).
  7. 07LabIn vitro (cells)Safety outcome

    KPV-loaded nanoparticles appeared nontoxic and biocompatible with intestinal cells.

    In plain wordsIn intestinal cells, nanoparticles loaded with KPV appeared nontoxic.

    Peptide
    KPV
    Outcome
    No significant changeToxicity and biocompatibility with intestinal cells
    Study

    n: not reported in source

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In addition, these KPV-loaded NPs appear to be nontoxic and biocompatible with intestinal cells.
    1 context sentence
    Summary · context
    Here, we loaded KPV into hyaluronic acid (HA)-functionalized polymeric nanoparticles (NPs).

Studies that did not test the peptide alone2

In this study, KPV was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking KPV.

  1. 08LabNot a test of KPV aloneIn vitro (cell-free)Other

    The HA-KPV nanoparticles had a particle size of about 272.3 nm.

    In plain wordsIn lab tests, nanoparticles carrying KPV had a size of about 272.3 nanometres.

    Peptide
    KPV
    Outcome
    Not applicableParticle size of HA-KPV-NPs
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology

    Measurements

    particle size
    272.3 nm
    HA-KPV-NPs

    Source sentences

    Summary
    The resultant HA-KPV-NPs had a desirable particle size (∼272.3 nm) and a slightly negative zeta potential (∼-5.3 mV).
    1 context sentence
    Summary · context
    Here, we loaded KPV into hyaluronic acid (HA)-functionalized polymeric nanoparticles (NPs).

    In this study, KPV was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking KPV.

  2. 09LabNot a test of KPV aloneIn vitro (cell-free)Other

    The HA-KPV nanoparticles had a slightly negative zeta potential of about -5.3 mV.

    In plain wordsIn lab tests, nanoparticles carrying KPV had a slightly negative surface charge.

    Peptide
    KPV
    Outcome
    Not applicableZeta potential of HA-KPV-NPs
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology

    Measurements

    zeta potential
    −5.3 mV
    HA-KPV-NPs

    Source sentences

    Summary
    The resultant HA-KPV-NPs had a desirable particle size (∼272.3 nm) and a slightly negative zeta potential (∼-5.3 mV).
    1 context sentence
    Summary · context
    Here, we loaded KPV into hyaluronic acid (HA)-functionalized polymeric nanoparticles (NPs).

    In this study, KPV was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking KPV.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.